Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:41:44.202Z.
Calculation as of: 2026-10-06T15:41:44.202Z.
Quote observation: 2026-10-06T15:40:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26b9d76e1867df839f3ea79fd47ae1c5236575fa33f8c6240ddbf9d3395e1dfe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$37.28M
PS Ratio
N/A
TTM Avg
65299.11
3Y Avg
21900.20
5Y Avg
13187.22
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | $36.80M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.28M | N/A | 65299.11 | 21900.20 | 13187.22 |
| Elutia Inc (ELUT)vs › | $35.54M | 2.93 | 2.34 | 2.93 | 2.48 |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.80M | 1.27 | 6.96 | 23.74 | 23.74 |
| DocGo Inc. (DCGO)vs › | $35.78M | 0.12 | 0.22 | 0.47 | 1.32 |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.15M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.10M | 0.45 | 0.32 | 0.77 | 1.11 |
| Accuray Incorporated (ARAY)vs › | $34.48M | 0.09 | 0.16 | 0.35 | 0.48 |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.34M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
